Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER). Edelman-Klapper H, et al. Among authors: yanai h. Gastroenterology. 2022 Feb;162(2):454-467. doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. Gastroenterology. 2022. PMID: 34717923 Free PMC article.
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y. Ben-Horin S, et al. Among authors: yanai h. Aliment Pharmacol Ther. 2012 Mar;35(6):714-22. doi: 10.1111/j.1365-2036.2012.04997.x. Epub 2012 Jan 30. Aliment Pharmacol Ther. 2012. PMID: 22288419 Free article.
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S. Yanai H, et al. Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25. Clin Gastroenterol Hepatol. 2015. PMID: 25066837
Significance of low level infliximab in the absence of anti-infliximab antibodies.
Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S. Ungar B, et al. Among authors: yanai h. World J Gastroenterol. 2015 Feb 14;21(6):1907-14. doi: 10.3748/wjg.v21.i6.1907. World J Gastroenterol. 2015. PMID: 25684959 Free PMC article.
925 results